Investor Relations

Investor Relations

Our Flashpoint. And Beyond…

Dova is a clinical-stage pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet medical need. Our lead drug candidate, avatrombopag, is a second generation orally administered thrombopoietin receptor agonist that we are developing for the treatment of thrombocytopenia across many different patient types.